AGM
PCSA icon

Alpine Global Management’s Processa Pharmaceuticals PCSA Stock Holding History

Alpine Global Management’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,137
Closed -$10.9K – 274
2025
Q2 		$10.9K Buy
+2,137
New +$14.3K ﹤0.01% 154

Other funds holding PCSA

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
SCA
Sassicaia Capital Advisers Jericho, New York $88.8M AUM 146.47% 1-Year Est. Return
MMA
Miracle Mile Advisors Los Angeles, California $8.53B AUM 21.43% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Alpine Global Management's PCSA Position: Q3 2025 in Review

Alpine Global Management sold out of Processa Pharmaceuticals (PCSA) in Q3 2025, closing a stake of 2,137 shares — an estimated $10.9K sold.

Alpine Global Management first reported a position in PCSA in Q2 2025 and held it in 1 quarter. The position peaked at $10.9K in Q2 2025. 13 funds tracked by Wall St. Rank hold PCSA as of Q3 2025.

  • Alpine Global Management reported no remaining Processa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Alpine Global Management sold 2,137 Processa Pharmaceuticals shares in Q3 2025, an estimated $10.9K.
  • Alpine Global Management first reported a position in Processa Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Alpine Global Management's Processa Pharmaceuticals position peaked at $10.9K in Q2 2025.
  • 13 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q3 2025.

Based on Alpine Global Management's 13F filing for Q3 2025, filed 14 Nov 2025.